A Study to Evaluate the Safety, Tolerability of DN1508052-01 in Advanced Solid Tumors

Summary

This is a phase I, open-label, multicenter study in adult patients with advanced solid tumors that have progressed despite standard therapy or for which no standard therapy exists. DN1508052-01 will be administered subcutaneously on Day 1, Day 8 and Day 15 in 28-day cycles. Other dose regimens may be explored based on the analysis of emerging PK, pharmacodynamics (PD) and safety data. This study is designed to determine the MTD, RP2D and investigate the safety, tolerability, PK, biomarkers, HPV status and ISR in DN1508052-01-treated patients.

Timeline

Start

2019-09-18

Primary completion

2022-08-30

Completion

2022-10-30

Drugs

Indications